Related Experiment Video
Updated: Apr 27, 2026

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
Patent foramen ovale treatment strategy: an Italian large prospective study
Brunilda Alushi1, Luigi Biasco, Fulvio Orzan
1aDivision of Cardiology, University of Turin, San Giovanni Battista Hospital, Turin, Italy bDivision of Cardiology, Maria Vittoria Hospital, Turin, Italy cDivision of Cardiology, Cardinal Massaia Hospital, Asti, Italy dDepartment of Neuroscience, San Giovanni Battista Hospital, Turin, Italy.
Insights
Percutaneous closure of patent foramen ovale (PFO) is chosen for large shunts, while medical treatment is preferred for multiple stroke risk factors. Older age, prior strokes, and atrial septal aneurysm predict adverse events, not PFO closure itself.
Area of Science:
- Cardiology
- Neurology
- Interventional Cardiology
Background:
- Patent foramen ovale (PFO) closure for cryptogenic stroke remains controversial.
- Understanding factors influencing treatment choice and adverse events is crucial.
Purpose of the Study:
- To evaluate factors associated with treatment strategy (percutaneous closure vs. medical management) in patients with PFO and cryptogenic stroke or TIA.
- To identify predictors of adverse events in this patient cohort.
Main Methods:
- Retrospective analysis of 418 patients with PFO and cryptogenic stroke or TIA.
- Multivariable logistic regression to assess treatment choice determinants and outcome predictors.
- Outcome defined as a composite of stroke, TIA, or all-cause mortality.
Main Results:
- Large interatrial right-to-left shunt favored percutaneous PFO closure (OR 4.79).
- Multiple cerebrovascular accident (CVA) risk factors favored medical treatment (OR 0.15).
- Older age (>55 years), previous CVAs, and atrial septal aneurysm (ASA) predicted adverse events (P < 0.05).
- Percutaneous PFO closure did not predict adverse events (OR 1.10, P = 0.81).
Conclusions:
- Treatment choice for PFO in cryptogenic stroke is influenced by shunt size and CVA risk factors.
- Older age, prior CVAs, and ASA are independent predictors of adverse outcomes.
- Percutaneous PFO closure was not found to be an independent predictor of adverse events in this study.
Aim:
There is still controversy regarding the benefit of percutaneous closure of patent foramen ovale (PFO) among patients with cryptogenic stroke. Here we aimed to evaluate the factors associated with treatment choice and predictors of adverse events in patients with cryptogenic stroke or transient ischemic attack (TIA) and PFO.
Methods:
Of 418 consecutive patients with PFO and cryptogenic stroke or TIA, 262 underwent percutaneous PFO closure, whereas 156 were medically treated. Multivariable logistic regression models were developed to evaluate factors influencing the treatment strategy and predictors of outcome, a composite of stroke, TIA or all-cause mortality.
Results:
Patients with large interatrial right-to-left shunt were more likely treated with percutaneous closure [odds ratio (OR) = 4.79, 95% confidence interval (2.73-8.42); P < 0.0001], whereas those with multiple cerebrovascular accident (CVA) risk factors were more likely treated medically [OR = 0.15 (0.03-0.60); P = 0.023]. Age greater than 55 years [OR = 2.70 (1.05-6.88); P = 0.04], previous CVAs [OR = 2.49 (1.03-6.02); P = 0.02] and atrial septal aneurism [ASA, OR = 2.64 (1.09-6.39); P = 0.02], but not percutaneous closure of PFO [OR = 1.10 (0.44-2.74); P = 0.81], were independent predictors of outcome.
Conclusion:
Among patients with cryptogenic stroke and PFO, the presence of large interatrial right-to-left shunt and multiple CVA risk factors influenced the treatment choice. Older age, multiple previous CVAs and ASA, but not PFO closure, independently predicted the composite outcome of cryptogenic stroke, TIA or all-cause mortality.
Related Concept Videos
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Mitral Stenosis IV: Nursing Management
Angle Closure Glaucoma: Treatment
Mitral Regurgitation IV: Nursing Management

